Lawoko A L, Johansson B, Hjalmarsson S, Christensson B, Ljungberg B, Al-Khalili L, Sjölund M, Pipkorn R, Fenyö E M, Blomberg J
Section of Virology, Department of Medical Microbiology, Lund University, Lund, Sweden.
J Med Virol. 1999 Oct;59(2):169-79.
IgG binding to V3 peptides and serum neutralising responses were studied in four HIV-1 infected individuals with progressive disease over a period of 31-70 months. The 18-20 mer peptides comprised residues 299-317 (numbering of HIV1 MN) in the N-terminal half of the V3 loop of the envelope glycoprotein gp120 and were derived from the sequences of autologous, as well as heterologous isolates. All four individuals studied lacked anti-V3 IgG binding to at least one autologous V3 sequence. V3 peptides to which autologous sera lacked binding IgG were all immunogenic in rabbits and induced antisera that were broadly cross-reactive by EIA and broadly cross-neutralising to primary HIV-1 isolates. This indicates that the peptides are immunogenic per se and that the respective human hosts have selective defects in recognising the corresponding V3 sequences. Despite the absence of antibody binding to autologous V3 peptides, the human sera had neutralising antibodies to autologous (three out of four cases), as well as heterologous isolates (all cases). Moreover, in vitro exposure of the patients' isolates to autologous neutralising serum or the homologous rabbit antiserum selected for variants with amino acid substitutions close to the crown of the V3 loop or in regions outside the sequence corresponding to peptides used for immunisation. The amino acid exchanges affected V3 positions known to be antigenic and which are also prone to change successively in infected persons. It is likely that neutralising antibodies recognise both linear and conformational epitopes in the V3 loop. Apparently, there are several, but restricted, numbers of ways for this structure to change its conformation and thereby give rise to neutralisation resistant viruses.
在4名患有进展性疾病的HIV-1感染者中,研究了IgG与V3肽的结合以及血清中和反应,研究时间为31至70个月。18 - 20聚体肽包含包膜糖蛋白gp120的V3环N端一半中299 - 317位的残基(HIV-1 MN编号),其来源于自体以及异源分离株的序列。所研究的4名个体均缺乏与至少一种自体V3序列结合的抗V3 IgG。自体血清缺乏结合IgG的V3肽在兔中均具有免疫原性,并诱导出通过酶免疫测定具有广泛交叉反应性且对原发性HIV-1分离株具有广泛交叉中和作用的抗血清。这表明这些肽本身具有免疫原性,并且相应的人类宿主在识别相应的V3序列方面存在选择性缺陷。尽管缺乏与自体V3肽结合的抗体,但人类血清对自体(4例中的3例)以及异源分离株(所有病例)均具有中和抗体。此外,将患者的分离株在体外暴露于自体中和血清或同源兔抗血清后,选择出了在V3环顶部附近或与用于免疫的肽对应的序列之外的区域发生氨基酸替换的变体。氨基酸交换影响了已知具有抗原性且在感染者中也容易相继发生变化的V3位置。中和抗体可能识别V3环中的线性和构象表位。显然,这种结构有几种但数量有限的方式来改变其构象,从而产生中和抗性病毒。